Clofibrate raises plasma apoprotein A-I and HDL-cholesterol concentrations.
In 10 hyperlipidaemic subjects who had been satisfactorily treated with clofibrate, stopping treatment led to significant reductions in plasma apoprotein A-I and high density lipoprotein cholesterol concentrations; resumption of treatment significantly raised both. The changes were therefore inversely related to those in the plasma cholesterol and triglyceride levels and were most prominent in hypertriglyceridaemic subjects.
D000368:Aged; D001059:Apoproteins / Q000097:blood*; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
D001059:Apoproteins; D008075:Lipoproteins, HDL; D014280:Triglycerides; D002784:Cholesterol; D002994:Clofibrate